In the present study, we used previous mutational analyses showing that distinct integrin-binding sites of CCN1 can function independently of one another [25–28] to determine the signaling pathway through which CCN1 mediates endocrine resistance in breast cancer. Here, CCN1 is linked to breast carcinoma.